CN120346304A - 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 - Google Patents

用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Info

Publication number
CN120346304A
CN120346304A CN202510423645.4A CN202510423645A CN120346304A CN 120346304 A CN120346304 A CN 120346304A CN 202510423645 A CN202510423645 A CN 202510423645A CN 120346304 A CN120346304 A CN 120346304A
Authority
CN
China
Prior art keywords
fold
amino acid
seq
agent
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510423645.4A
Other languages
English (en)
Chinese (zh)
Inventor
亚瑟·沙赫特
莫希特·马图尔
大卫·威廉·奥尔达克
苏珊·斯隆
吉尔·亚伯勒
妮可·阿克拉莫夫
黛安娜·马
威廉·C·塔布斯
米凯拉·舒尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of CN120346304A publication Critical patent/CN120346304A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202510423645.4A 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 Pending CN120346304A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases
CN202380019852.2A CN119013034A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202380019852.2A Division CN119013034A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Publications (1)

Publication Number Publication Date
CN120346304A true CN120346304A (zh) 2025-07-22

Family

ID=85476118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510423645.4A Pending CN120346304A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白
CN202380019852.2A Pending CN119013034A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380019852.2A Pending CN119013034A (zh) 2022-02-11 2023-02-10 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白

Country Status (10)

Country Link
US (1) US20230390360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475875A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506173A (cg-RX-API-DMAC7.html)
KR (1) KR20240148001A (cg-RX-API-DMAC7.html)
CN (2) CN120346304A (cg-RX-API-DMAC7.html)
AU (1) AU2023219773A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243493A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009868A (cg-RX-API-DMAC7.html)
TW (1) TW202400218A (cg-RX-API-DMAC7.html)
WO (1) WO2023154870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2026154422A1 (en) * 2025-01-17 2026-07-23 Otsuka Pharmaceutical Company, Ltd. Il-2-fc fusion protein for use in treating autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
KR20240148001A (ko) 2024-10-10
TW202400218A (zh) 2024-01-01
AU2023219773A1 (en) 2024-08-01
CA3243493A1 (en) 2023-08-17
JP2025506173A (ja) 2025-03-07
EP4475875A1 (en) 2024-12-18
CN119013034A (zh) 2024-11-22
MX2024009868A (es) 2024-08-20
WO2023154870A1 (en) 2023-08-17
US20230390360A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
CN119013034A (zh) 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白
US20250059249A1 (en) Interleukin-2 agents and uses thereof
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
DK1868635T3 (en) METHODS OF TREATING IMMUNE DISEASES IN CONNECTION WITH ORGAN TRANSPLANTATION WITH SOLUBLE, Mutating CTLA4 MOLECULES
US20220226442A1 (en) Interleukin-2 agents and uses thereof
RS62630B9 (sr) Modulatori aktivnosti komplementa
JP2023055875A (ja) Hiv融合体を標的とするポリペプチド
US11603387B2 (en) SOCS mimetics for the treatment of diseases
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
HK40124714A (en) Interleukin-2 muteins for the treatment of autoimmune diseases
HK40113125A (en) Interleukin-2 muteins for the treatment of autoimmune diseases
JP2025530309A (ja) 自閉症スペクトラム障害の処置に使用するためのインターロイキン-2
CN116635055A (zh) 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物
HK40098728A (en) Interleukin-2 mutants and uses thereof
CN116997351A (zh) 白介素-2突变体及其用途
HK40110548A (en) Methods of using interleukin-2 agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124714

Country of ref document: HK